aTYR PHARMA (ATYR) Operating Expenses (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Operating Expenses data on file, last reported at -$644000.0 in Q1 2026.

• Quarterly Operating Expenses rose 27.8% year-over-year to -$644000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.9 million (down 118.84% YoY) and the FY2025 annual result came in at -$3.5 million, down 105.14% from the prior year.
• Operating Expenses advanced to -$644000.0 in Q1 2026, from -$66.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $71.2 million in Q4 2024 to a low of -$66.5 million in Q4 2025.
• A 5-year average of $8.1 million and a median of $13.0 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses slumped 339.07% — and 2024, when it surged 262.4%.
• Tracing ATYR's Operating Expenses over 5 years: stood at $18.3 million in 2022, then plunged by 339.07% to -$43.8 million in 2023, then surged by 262.4% to $71.2 million in 2024, then sank by 193.45% to -$66.5 million in 2025, then jumped by 99.03% to -$644000.0 in 2026.
• The last three Operating Expenses figures came in at -$644000.0 (Q1 2026), -$66.5 million (Q4 2025), and $26.9 million (Q3 2025), per Business Quant data.